Overcoming drug resistance with specific nano scales to targeted therapy: Focused on metastatic cancers

被引:2
|
作者
Kadhum, Wesam R. [1 ,2 ]
Majeed, Ali A. [3 ]
Saleh, Raed Obaid [4 ]
Ali, Eyhab [5 ]
Alhajlah, Sharif [6 ]
Alwaily, Enas R. [7 ]
Mustafa, Yasser Fakri [8 ]
Ghildiyal, Pallavi [9 ]
Alawadi, Ahmed [10 ,11 ,12 ]
Alsalamy, Ali [13 ]
机构
[1] Kut Univ Coll, Dept Pharm, Kut 52001, Wasit, Iraq
[2] Kut Univ Coll, Adv Res Ctr, Kut 52001, Wasit, Iraq
[3] Univ Kufa, Fac Sci, Dept Pathol Anal, Najaf, Iraq
[4] Al Maarif Univ Coll, Dept Med Lab Tech, Al Anbar, Iraq
[5] Al Zahraa Univ Women, Pharm Dept, Karbala, Iraq
[6] Shaqra Univ, Coll Appl Med Sci, Dept Med Labs, Shaqra 11961, Saudi Arabia
[7] Al Ayen Univ, Coll Pharm, Microbiol Res Grp, Thi Qar, Iraq
[8] Univ Mosul, Coll Pharm, Dept Pharmaceut Chem, Mosul, Iraq
[9] Uttaranchal Univ, Uttaranchal Inst Pharmaceut Sci, Dehra Dun, Uttarakhand, India
[10] Islamic Univ, Coll Tech Engn, Najaf, Iraq
[11] Islamic Univ Al Diwaniyah, Coll Tech Engn, Al Diwaniyah, Iraq
[12] Islamic Univ Babylon, Coll Tech Engn, Babylon, Iraq
[13] Imam Jaafar Al Sadiq Univ, Coll Tech Engn, Al Muthanna, Iraq
关键词
Targeted Therapy; Metastatic cancer; Scales; Nano drug; Signaling; SOLID LIPID NANOPARTICLES; ENHANCED PERMEABILITY; REXIN-G; GENETIC-HETEROGENEITY; INTRINSIC RESISTANCE; MULTIDRUG-RESISTANCE; DELIVERY SYSTEMS; SINGLE-AGENT; LUNG-CANCER; IN-VITRO;
D O I
10.1016/j.prp.2024.155137
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Metastatic cancer, which accounts for the majority of cancer fatalities, is a difficult illness to treat. Currently used cancer treatments include radiation therapy, chemotherapy, surgery, and targeted treatment (immune, gene, and hormonal). The disadvantages of these treatments include a high risk of tumor recurrence and surgical complications that may result in permanent deformities. On the other hand, most chemotherapy drugs are small molecules, which usually have unfavorable side effects, low absorption, poor selectivity, and multi-drug resistance. Anticancer drugs can be delivered precisely to the cancer spot by encapsulating them to reduce side effects. Stimuli-responsive nanocarriers can be used for drug release at cancer sites and provide target-specific delivery. As previously stated, metastasis is the primary cause of cancer-related mortality. We have evaluated the usage of nano-medications in the treatment of some metastatic tumors.
引用
收藏
页数:10
相关论文
共 50 条
  • [41] Nano-Based Drug Delivery and Targeting to Overcome Drug Resistance of Ovarian Cancers
    McFadden, Melayshia
    Singh, Santosh Kumar
    Oprea-Ilies, Gabriela
    Singh, Rajesh
    CANCERS, 2021, 13 (21)
  • [42] Reversing Resistance to Checkpoint Inhibitors and Targeted Therapy in Metastatic Melanoma
    Sznol, Mario
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (07) : 408 - 410
  • [43] The cost of one added day of survival by targeted therapy in metastatic colorectal cancers
    Guirgis, Helmy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [44] The impact of number of cycles of targeted therapy on cost evaluation in metastatic colorectal cancers
    Guirgis, Helmy M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [45] Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer
    Kinnel, Briana
    Singh, Santosh Kumar
    Oprea-Ilies, Gabriela
    Singh, Rajesh
    CANCERS, 2023, 15 (04)
  • [46] Editorial: Mechanisms of drug resistance to targeted therapy in malignancies
    Hamaji, Masatsugu
    FRONTIERS IN ONCOLOGY, 2024, 14
  • [47] The role of RICTOR amplification in targeted therapy and drug resistance
    Zhao, Deze
    Jiang, Man
    Zhang, Xiaochun
    Hou, Helei
    MOLECULAR MEDICINE, 2020, 26 (01)
  • [48] The role of RICTOR amplification in targeted therapy and drug resistance
    Deze Zhao
    Man Jiang
    Xiaochun Zhang
    Helei Hou
    Molecular Medicine, 2020, 26
  • [49] Mechanisms of resistance to tyrosine kinase inhibitor-targeted therapy and overcoming strategies
    Ou, Xuejin
    Gao, Ge
    Habaz, Inbar A.
    Wang, Yongsheng
    MEDCOMM, 2024, 5 (09):
  • [50] Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies
    San Roman-Gil, Maria
    Pozas, Javier
    Rosero-Rodriguez, Diana
    Chamorro-Perez, Jesus
    Ruiz-Granados, Alvaro
    Caracuel, Ignacio Ruz
    Grande, Enrique
    Molina-Cerrillo, Javier
    Alonso-Gordoa, Teresa
    CANCER TREATMENT REVIEWS, 2022, 105